Evaluation of the humoral immune response induced by vaccination for canine distemper and parvovirus: a pilot study

• Published in: BMC veterinary research Vol. 14; no. 1; pp. 348 - 8
• Main Authors: Vila Nova, Beatriz, Cunha, Eva, Sepúlveda, Nuno, Oliveira, Manuela, São Braz, Berta, Tavares, Luis, Almeida, Virgílio, Gil, Solange
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 16-11-2018; BioMed Central; BMC
• Subjects: Adenoviruses; Age; Animals; Antibodies; Antibodies, Viral - blood; Canine distemper; Canine parvovirus; Care and treatment; CDV; CPV; Distemper - immunology; Distemper - prevention & control; Distemper Virus, Canine - immunology; Dog diseases; Dog Diseases - immunology; Dog Diseases - prevention & control; Dog Diseases - virology; Dogs; Enzyme-linked immunosorbent assay; Enzyme-Linked Immunosorbent Assay - veterinary; Female; Health aspects; Humoral immunity; Immune response; Immune response (humoral); Immunity, Humoral - immunology; Immunoglobulins; Infections; Male; Maternal antibodies; Mortality; Neutralization; Parvoviridae Infections - immunology; Parvoviridae Infections - prevention & control; Parvoviridae Infections - veterinary; Parvovirus, Canine - immunology; Parvoviruses; Physiological aspects; Pilot Projects; Prevention; Schedules; Seroconversion; Seroprevalence; Vaccination; Vaccine efficacy; Vaccines; Veterinary vaccines; Viral infections; Viral Vaccines - therapeutic use; Viruses; Seroreversion; CDV; Maternal antibodies; Vaccination; CPV; Humoral immunity; Seroprevalence
• ISSN: 1746-6148; 1746-6148
• DOI: 10.1186/s12917-018-1673-z

Canine Distemper Virus (CDV) and Canine Parvovirus (CPV) lead to infections with high mortality rates in dogs. These viruses affect unvaccinated dogs or dogs with incomplete vaccination protocols. Vaccination plays an important role in reducing death rates, preventing clinical cases and controlling the spread of virus However, the efficacy of vaccination might be affected by different factors including vaccine scheduling and the neutralization of the vaccine targets by maternal antibodies. In face of these factors, the main goals of this study are (i) to investigate the antibody responses of puppies undergoing different primary vaccination protocols against CPV and CDV and (ii) to estimate the time until seroreversion in adult dogs unvaccinated for at least 3 years.
Antibody protection against CDV and CPV was evaluated in a total of 20 dogs: 5 puppies that initiated immunization at 6 weeks after birth (group A), 8 animals that started vaccination between 8 and 12 weeks of age (group B), and 7 adult dogs that have not been vaccinated for at least 3 years (group C). Blood samples were collected from each animal, with 3 to 4 weeks apart. Antibody responses were measured using indirect ELISA. In the second immunization point, no significant differences were found between the seroconversion of groups A and B for each viral infection (p = 0.81 and 0.20 for CDV and CPV, respectively). In the third immunization, there was evidence for a shorter time to achieve a protective titer against CPV in group B when compared to group A (p = 0.015). Similar evidence was not found for CDV (p-value = 0.41). In Group C, the average time until seroveversion was estimated at 2.86 years and 7.63 years for CDV and CPV, respectively.
Vaccine response to CDV and CPV is specific in each individual. Effective immune protection in primary vaccination depends mainly on the initial titer of maternal antibodies acquired by the neonate. Other factors such as environmental exposure, immunization schedules and immune system activity influence the duration of immunity in adult dogs. The variability found reinforces the need to determine individual humoral immunity levels in order to assess vaccine efficacy.